Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nutrition
Published in: European Journal of Nutrition 1/2016

01-02-2016 | Original Contribution

Bifidobacterium pseudocatenulatum CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis

Authors: Alba Moratalla, Isabel Gómez-Hurtado, Ángela Moya-Pérez, Pedro Zapater, Gloria Peiró, José M. González-Navajas, Eva Maria Gómez Del Pulgar, José Such, Yolanda Sanz, Rubén Francés

Published in: European Journal of Nutrition | Issue 1/2016

Login to get access

Abstract

Background

Intestinal homeostasis plays an important role in bacteria-derived complications in cirrhosis. Intestinal lymphocytes are responsible for immune effector functions and can be modulated by certain probiotics. We evaluate the interaction between Bifidobacterium pseudocatenulatum CECT7765 and intestinal lymphocytes in mice with cirrhosis.

Animals and methods

Cirrhosis was induced by intragastrical administration of carbon tetrachloride in Balb/C mice. One week prior to laparotomy, animals received B. pseudocatenulatum CECT7765 (107, 109 or 1010 cfu/daily) or placebo. Chemokine receptor and cytokine expression were evaluated in intestinal lymphocytes. Gut permeability was studied by FITC-LPS recovery in vivo. Luminal antigens, inflammation and functional markers were evaluated in liver samples.

Results

Bifidobacterium pseudocatenulatum CECT7765 decreased the expression of pro-inflammatory chemokine receptors CCR6, CCR9, CXCR3 and CXCR6 in intestinal lymphocytes from cirrhotic mice in a concentration-dependent manner. The bifidobacterial strain induced a shift towards an anti-inflammatory cytokine profile in this cell subset. B. pseudocatenulatum CECT7765-induced inflammatory modulation was TLR2-mediated, as in vitro TLR2 blockade inhibited the reduction of TNF-alpha and its receptors and the increase of IL-10 and IL-10 receptor secretion. The recovery rate of administered fluorescence-labelled endotoxin was significantly and dose-dependently lowered with the bifidobacterial strain. The reduced intestinal permeability was associated with a decreased burden of bacterial antigens in the liver of mice treated with B. pseudocatenulatum CECT7765. Liver function and inflammation were improved with the use of the bifidobacterial strain at the highest dose tested (1010 cfu).

Conclusion

Bifidobacterium pseudocatenulatum CECT7765 improves gut homeostasis and prevents gut-derived complications in experimental chronic liver disease.
Appendix
Available only for authorised users
Literature
1.
Berg RD (1992) Bacterial translocation from the gastrointestinal tract. J Med 23:217–244
2.
Wiest R, Garcia-Tsao G (2005) Bacterial translocation (BT) in cirrhosis. Hepatology 41:422–433CrossRef
3.
Yan AW, Fouts DE, Brandl J, Starkel P, Torralba M, Schott E et al (2011) Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 53:96–105CrossRef
4.
Gomez-Hurtado I, Santacruz A, Peiro G, Zapater P, Gutierrez A, Perez-Mateo M et al (2011) Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis. PLoSOne 6:e23037CrossRef
5.
Kirpich IA, McClain CJ (2012) Probiotics in the treatment of the liver diseases. J Am Coll Nutr 31:14–23CrossRef
6.
Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R (2008) Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 48:945–951CrossRef
7.
Pereg D, Kotliroff A, Gadoth N, Hadary R, Lishner M, Kitay-Cohen Y (2011) Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition 27:177–181CrossRef
8.
Moratalla A, Gomez-Hurtado I, Santacruz A, Moya A, Peiro G, Zapater P, et al. (2014) Protective effect of Bifidobacterium pseudocatenulatum CECT7765 against induced bacterial antigen translocation in experimental cirrhosis. Liver Int 34:850–858CrossRef
9.
Agace WW (2006) Tissue-tropic effector T cells: generation and targeting opportunities. Nat Rev Immunol 6:682–692CrossRef
10.
de Kivit S, Tobin MC, Forsyth CB, Keshavarzian A, Landay AL (2014) Regulation of intestinal immune responses through TLR activation: implications for pro- and prebiotics. Front Immunol 5:60CrossRef
11.
Jeon SG, Kayama H, Ueda Y, Takahashi T, Asahara T, Tsuji H et al (2012) Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog 8:e1002714CrossRef
12.
Isono A, Katsuno T, Sato T, Nakagawa T, Kato Y, Sato N et al (2007) Clostridium butyricum TO-A culture supernatant downregulates TLR4 in human colonic epithelial cells. Dig Dis Sci 52:2963–2971CrossRef
13.
Hayashi A, Sato T, Kamada N, Mikami Y, Matsuoka K, Hisamatsu T et al (2013) A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host Microbe 13:711–722CrossRef
14.
Mazmanian SK, Round JL, Kasper DL (2008) A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453:620–625CrossRef
15.
Vizoso Pinto MG, Rodriguez Gomez M, Seifert S, Watzl B, Holzapfel WH, Franz CM (2009) Lactobacilli stimulate the innate immune response and modulate the TLR expression of HT29 intestinal epithelial cells in vitro. Int J Food Microbiol 133:86–93CrossRef
16.
Furrie E, Macfarlane S, Thomson G, Macfarlane GT, Microbiology and Gut Biology Group et al (2005) Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 115:565–574CrossRef
17.
Kingma SD, Li N, Sun F, Valladares RB, Neu J, Lorca GL (2011) Lactobacillus johnsonii N6.2 stimulates the innate immune response through Toll-like receptor 9 in Caco-2 cells and increases intestinal crypt Paneth cell number in biobreeding diabetes-prone rats. J Nutr 141:1023–1028CrossRef
18.
Such J, Frances R, Munoz C, Zapater P, Casellas JA, Cifuentes A et al (2002) Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 36:135–141CrossRef
19.
Guarner C, Gonzalez-Navajas JM, Sanchez E, Soriano G, Frances R, Chiva M et al (2006) The detection of bacterial DNA in blood of rats with CCl(4)-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology 44:633–639CrossRef
20.
Gautreaux MD, Gelder FB, Deitch EA, Berg RD (1995) Adoptive transfer of T lymphocytes to T-cell-depleted mice inhibits Escherichia coli translocation from the gastrointestinal tract. Infect Immun 63:3827–3834
21.
Choudhry MA, Fazal N, Goto M, Gamelli RL, Sayeed MM (2002) Gut-associated lymphoid T cell suppression enhances bacterial translocation in alcohol and burn injury. Am J Physiol Gastrointest Liver Physiol 282:G937–G947CrossRef
22.
Stenstad H, Ericsson A, Johansson-Lindbom B, Svensson M, Marsal J, Mack M et al (2006) Gut-associated lymphoid tissue-primed CD4 + T cells display CCR9-dependent and -independent homing to the small intestine. Blood 107:3447–3454CrossRef
23.
Chu PS, Nakamoto N, Ebinuma H, Usui S, Saeki K, Matsumoto A et al (2013) C-C motif chemokine receptor 9 positive macrophages activate hepatic stellate cells and promote liver fibrosis in mice. Hepatology 58:337–350CrossRef
24.
Hammerich L, Bangen JM, Govaere O, Zimmermann HW, Gassler N, Huss S et al (2014) Chemokine receptor CCR6-dependent accumulation of gammadelta T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology 59:630–642CrossRef
25.
Helwig U, Lammers KM, Rizzello F, Brigidi P, Rohleder V, Caramelli E et al (2006) Lactobacilli, Bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. World J Gastroenterol 12:5978–5986
26.
Medina M, Izquierdo E, Ennahar S, Sanz Y (2007) Differential immunomodulatory properties of Bifidobacterium logum strains: relevance to probiotic selection and clinical applications. Clin Exp Immunol 150:531–538CrossRef
27.
Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T et al (2003) Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 171:4984–4989CrossRef
28.
Dillon S, Agrawal A, Van Dyke T, Landreth G, McCauley L, Koh A et al (2004) A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol 172:4733–4743CrossRef
29.
Redecke V, Hacker H, Datta SK, Fermin A, Pitha PM, Broide DH et al (2004) Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol 172:2739–2743CrossRef
30.
Plantinga TS, van Maren WW, van Bergenhenegouwen J, Hameetman M, Nierkens S, Jacobs C et al (2011) Differential Toll-like receptor recognition and induction of cytokine profile by Bifidobacterium breve and Lactobacillus strains of probiotics. Clin Vaccine Immunol 18:621–628CrossRef
31.
Hartmann P, Haimerl M, Mazagova M, Brenner DA, Schnabl B (2012) Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. Gastroenterology 143(1330–1340):e1331
32.
Frances R, Zapater P, Gonzalez-Navajas JM, Munoz C, Cano R, Moreu R et al (2008) Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 47:978–985CrossRef
33.
Moorthy G, Murali MR, Devaraj SN (2009) Lactobacilli facilitate maintenance of intestinal membrane integrity during Shigella dysenteriae 1 infection in rats. Nutrition 25:350–358CrossRef
34.
Khailova L, Dvorak K, Arganbright KM, Halpern MD, Kinouchi T, Yajima M et al (2009) Bifidobacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 297:G940–G949CrossRef
35.
Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N et al (2009) Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 296:G1140–G1149CrossRef
36.
Zhou YK, Qin HL, Zhang M, Shen TY, Chen HQ, Ma YL et al (2012) Effects of Lactobacillus plantarum on gut barrier function in experimental obstructive jaundice. World J Gastroenterol 18:3977–3991CrossRef
37.
Sanchez E, Nieto JC, Boullosa A, Vidal S, Sancho FJ, Rossi G, et al. (2014) VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. Liver Int 34:1504–1512CrossRef
38.
Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P et al (2009) VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 49:989–997CrossRef
39.
Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB et al (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37:343–350CrossRef
Metadata
Title
Bifidobacterium pseudocatenulatum CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis
Authors
Alba Moratalla
Isabel Gómez-Hurtado
Ángela Moya-Pérez
Pedro Zapater
Gloria Peiró
José M. González-Navajas
Eva Maria Gómez Del Pulgar
José Such
Yolanda Sanz
Rubén Francés
Publication date
01-02-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nutrition / Issue 1/2016
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-015-0837-x

Other articles of this Issue 1/2016

European Journal of Nutrition 1/2016 Go to the issue

Original Contribution

The traditional Japanese dietary pattern and longitudinal changes in cardiovascular disease risk factors in apparently healthy Japanese adults

Original Contribution

Skeletal muscles respond differently when piglets are offered a diet 30 % deficient in total sulfur amino acid for 10 days

Original Contribution

Soy and isoflavone consumption and risk of gastrointestinal cancer: a systematic review and meta-analysis

Original Contribution

Early developmental exposure to high fructose intake in rats with NaCl stimulation causes cardiac damage

Original Contribution

Effect of low-dose selenium on thyroid autoimmunity and thyroid function in UK pregnant women with mild-to-moderate iodine deficiency

Original Contribution

The inverse association between serum 25-hydroxyvitamin D and mortality may be modified by vitamin A status and use of vitamin A supplements
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits